IRB #
STUDY00019434
Title
[NCI CIRB] LUNGMAP - A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer
Principal Investigator
Jeremy Cetnar
Study Purpose
The purpose of this study is to determine if targeted or immunotherapy treatment will have an effect on specific genes and proteins in the participants tumor.
Medical Condition(s)
Non-Small Cell Lung Cancer
Eligibility Criteria
1- Pathologically proven Stage IV, or recurrent, Non-Small Cell Lung Cancer
2- Received at least one line of systemic therapy at any stage of disease and have progressed during, or following, their most recent line of therapy OR Current treatment must be for Stage IV, or recurrent disease, and patient must have received at least one dose of current regimen.
3- Must have adequate tumor tissue available per protocol
4- If patient has a known EGFR mutation, ALK gene fusion, ROS1 gene rearrangement or BRAF mutation are deemed not eligible unless they have progressed following all standard of care targeted therapy.
Age Range
18 - 99
Healthy Volunteers Needed
No
Duration of Participation
Participants will be followed until sub-study registration, 3 years from registration, or death, whichever comes first.
Minors Included
No
Contact
Knight Information Line - trials@ohsu.edu or 503-494-1080
Sponsor
SWOG
Recruitment End
12/31/2028
Compensation Provided
No
Go Back